Effects of Mecobalamin on Hyperhomocysteinemia in Patients with Type 2 Diabetic Nephropathy

LI Yan-zhi,REN Li-qun,SUN Zi-lin
DOI: https://doi.org/10.3969/j.issn.1007-7669.2007.05.003
2007-01-01
Abstract:AIM:To investigate the association between the plasma homocysteine(HCY)level and diabetic nephropathy(DN)of type 2 diabetic patients,and the effects of mecobalamin on hyperhomocysteinem- ia in these patients.METHODS:Eighty-seven patients with type 2 diabetic were recruited to participate the study.The patients were assigned to three groups according to urinary albumin excretion rate(UAER):group A (n=30),UAER≤30μg·mg~(-1)·Cr~(-1);group B(n=29),UAER>30-<300μg·mg~(-1)·Cr~(-1);group C(n= 28),UAER≥300μg·mg~(-1)·Cr~(-1).Another 24 patients without diabetes mellitus were participated as the control group.On the same basal treatment,all groups of patients were treated with meobalamin for 7 wk:500μg,iv, bid for 3 wk and followed by 500μg,po,rid for 4 wk.The levels of HCY,UAER,lipoprotein(a)etc at before and 3,7 wk after treatment were determined.RESULTS:Before the treatment,the level of HCY in group A was similar or slightly higher to that in control group(P>0.05),while HCY in group B and C were much higher than that of control group(P<0.01).After treatment with meobalamin for 7 wk,the levels of HCY and UAER in group B and C decreased significantly(P<0.01),and the level of lipoprotein(a)in group C decreased obviously too(P<0.01)while that in group B showed no obvious changes(P>0.05).The level of HCY was positively related to those of UAER and lipoprotein(a)(r=0.42,0.33)and negatively related to that of endogeneous creatinine clearance(r=-0.46),all P<0.01.CONCLUSION:The patients with DN have hyperhomocysteinemia in initial and clinical stages,and the level of plasma HCY is positively related to UAER. Mecobalamin can decrease the levels of HCY in DN patients and thus with a certain extent of urinary albumin.
What problem does this paper attempt to address?